Laurie Deerfield
Psychiatry · Holly Hill, FLNPI 1689676207
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $566 and has fallen 68.5% since, to $178 in 2022.
Across 113 payments — averaging $13.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$209
- Takeda Pharmaceuticals U.S.A., Inc.$163
- Otsuka America Pharmaceutical, Inc.$139
- AbbVie$99
- Arbor Pharmaceuticals, Inc.$90
- Johnson & Johnson$87
- plus $741 from 17 others
What the payments were for
- Food & beverage$1,525100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 18 | $209 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $163 |
| Otsuka America Pharmaceutical, Inc. | 7 | $139 |
| AbbVie(2 entities) | 7 | $99 |
| Arbor Pharmaceuticals, Inc. | 7 | $90 |
| Johnson & Johnson | 7 | $87 |
| Teva Pharmaceuticals USA, Inc. | 5 | $68 |
| Avanir Pharmaceuticals, Inc. | 5 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $66 |
| Lundbeck LLC | 5 | $65 |
| Alkermes, Inc. | 4 | $55 |
| Merck | 4 | $54 |
| Shire North American Group Inc | 4 | $52 |
| Bausch Health US, LLC | 3 | $43 |
| Orexo US, Inc. | 3 | $42 |
| Eisai Inc. | 3 | $39 |
| Adlon Therapeutics L.p. | 3 | $39 |
| Jazz Pharmaceuticals Inc. | 3 | $35 |
| Indivior Inc. | 2 | $28 |
| Sun Pharmaceutical Industries Inc. | 2 | $27 |
| Ironshore Pharmaceuticals Inc. | 2 | $25 |
| OWP Pharmaceuticals, Inc. | 2 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
How this compares
$1,529 in reported general payments places this provider in the 70th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 11 | $380 |
| Clonazepam | 23 | $145 |
| Escitalopram Oxalate | 11 | $51 |
| Lamotrigine | 13 | $46 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Holly Hill
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.